跳至主要内容
临床试验/NCT02340013
NCT02340013已完成4 期

The Effect of Endometrial Shedding With Medroxyprogesterone Acetate Prior to Ovulation Induction With Clomiphene Citrate in Oligo-ovulatory and Anovulatory Women: a Pilot Study

Samuel Lunenfeld Research Institute, Mount Sinai Hospital2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2013年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
50
试验地点
2
主要终点
Composite measure of study feasibility

研究概览

简要总结

This is a pilot study examining the feasibility of implementing a large randomized control trial looking at the effect of endometrial shedding with medroxyprogesterone acetate compared to no pre-treatment in women taking clomiphene citrate for ovulation induction for infertility due to oligo-ovulation or anovulation.

详细描述

The purpose of this pilot study is to assess the feasibility of implementing a randomized controlled trial assessing the effect of giving medroxyprogesterone acetate (MPA) to induce a withdrawal bleed compared to a control group of women not receiving MPA on pregnancy rates prior to ovulation induction with clomiphene citrate in oligo-ovulatory and anovulatory women. The primary outcome measure is the effective implementation of the study including a measure of time to recruit 50 patients, physician, nursing and patient compliance rate with the study protocol, and patient satisfaction. Secondary outcome measures include the pregnancy rate per ovulation (where pregnancy is defined as a positive fetal heart rate on ultrasound 2 weeks after a positive pregnancy test), the ovulation rate per cycle started, conception rate per cycle started (where conception is defined as a positive beta-human chorionic gonadotropin level), conception rate per ovulation, time to complete 3 stimulation cycles and endometrial thickness at time of luteinizing hormone surge.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Care Provider)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Oligo-ovulation defined as having less than or equal to 8 menstrual cycles in the past year or inter-menstrual periods of 45 days or longer
  • general good health
  • ability to have timed intercourse or intrauterine insemination
  • no evidence of tubal dysfunction
  • no evidence of a uterine cavity abnormality
  • no evidence of male factor infertility

排除标准

  • a baseline ultrasound showing an endometrial lining greater than 1.0 cm
  • a baseline ultrasound showing an endometrial lining of less than 0.5 cm
  • a positive progesterone level at baseline bloodwork
  • a positive beta human chorionic gonadotropin level at baseline bloodwork
  • body mass index of greater than 40
  • women who have previously taken clomiphene citrate for ovulation induction within the last 6 months
  • women who are taking metformin
  • women who are taking a progestin for luteal phase support.

研究组 & 干预措施

Medroxyprogesterone acetate

Active Comparator

Medroxyprogesterone acetate 10mg per os x 10 days prior to starting clomiphene citrate 50mg once daily days 3 - 7 of bleeding after stopping medroxyprogesterone acetate

干预措施: Medroxyprogesterone acetate (Drug)

结局指标

主要结局

Composite measure of study feasibility

时间窗: 2 years

Time to recruit 50 patients; physician, nursing and patient compliance rate with the study protocol; and patient satisfaction.

次要结局

  • pregnancy rate per ovulation(2 years)
  • ovulation rate per cycle started,(2 years)
  • conception rate per cycle started(2 years)
  • conception rate per ovulation(2 years)
  • time to complete 3 stimulation cycles(2 years)
  • time to pregnancy(2 years)
  • endometrial thickness at time of luteinizing hormone surge(2 years)

研究者

发起方
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验